We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CareDx, QIAGEN Collaborate
News

CareDx, QIAGEN Collaborate

CareDx, QIAGEN Collaborate
News

CareDx, QIAGEN Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CareDx, QIAGEN Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CareDx, Inc. has announced it has signed a memorandum of understanding to collaborate with QIAGEN. Under the terms of this commercial collaboration, CareDx will make available to Human Leukocyte Antigen (HLA) laboratories worldwide the proprietary QIAGEN QIAxcel Advanced Instrumentation together with its proprietary Olerup SSP® kits and SCORE™ software. This combined offering will provide transplant labs an additional option for processing and data entry for HLA typing.

"We are excited to be working with QIAGEN, a leader in diagnostic technology. This collaboration fits well with our strategy to partner with leading innovative solution providers and enhance the transplant lab testing workflow," said Anders Karlsson, Chief International Business Officer at CareDx.

"CareDx is a recognized leader in transplant diagnostics. Our collaboration will allow us to bring our QIAxcel solutions to HLA labs around the globe using the CareDx commercial channel," said Thierry Bernard, Senior Vice President and Head of QIAGEN's Molecular Diagnostics Business Area. Financial terms of the collaboration were not disclosed.

Advertisement